Doctors Favor CPAP, Patients Favor Tirzepatide for Comorbid Obesity, Sleep Apnea
By Elana Gotkine HealthDay Reporter
MONDAY, June 9, 2025 -- Both continuous positive airway pressure (CPAP) and tirzepatide are acceptable treatments for comorbid obesity and obstructive sleep apnea (COBOSA), with providers favoring CPAP and patients preferring tirzepatide, according to a study presented at SLEEP 2025, the annual meeting of the Associated Professional Sleep Societies, held from June 8 to 11 in Seattle.
Ahmed Khalaf, from the University of California, San Diego, and colleagues examined patient and provider attitudes toward use of CPAP and tirzepatide for COBOSA using an online survey. The survey was distributed to 17 sleep medicine providers and about 6,500 patients aged 21 years or older seen at a sleep clinic in the preceding two years.
Seventeen providers and 365 patients responded to the survey. The researchers found that 53 percent of patients had COBOSA; 23 percent had current/past use of tirzepatide and/or semaglutide, and 78 percent had current/past use of CPAP. The researchers found that more than 75 percent of patients and providers reported that CPAP and tirzepatide were somewhat/very acceptable. Similar acceptability was reported by patients for both therapies, while for CPAP, providers were more accepting than patients (88 versus 59 percent reported CPAP as very acceptable). If evidence demonstrated equal effectiveness, patients leaned toward tirzepatide (48 versus 35 percent), while providers favored CPAP (53 versus 26 percent). Combination therapy was supported by both groups, but patients were less enthusiastic (61 versus 88 percent).
"Understanding these differences is critical for shared decision-making throughout the care plan, which may ultimately impact adherence and treatment success," Khalaf said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2025
Read this next
Less 'Experienced Weight Stigma' After Bariatric Surgery Aids Mental Health
FRIDAY, June 6, 2025 -- Experienced weight stigma (EWS) improves from pre- to post-metabolic bariatric surgery (MBS), according to a study published online June 5 in Health...
Obesity Linked to Subsequent Neoplasms in Childhood Cancer Survivors
FRIDAY, June 6, 2025 -- Body mass index (BMI) and physical activity are associated with the risk for subsequent neoplasms among childhood cancer survivors, according to a study...
GLP-1 Receptor Agonist Exposure Linked to Neovascular AMD in Patients With Diabetes
FRIDAY, June 6, 2025 -- For patients with diabetes, exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased risk for incident neovascular...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.